Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.…
Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
Orchestra BioMed Holdings (NASDAQ: OBIO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 86 employees.
The shares were at 6.580 USD on 20 November 2026, up 72.7% over 52 weeks. Its 52-week range is 3.460 USD to 7.825 USD: the price is 15.9% below the high and 90.2% above the low.
Its market capitalisation is 517.88M USD.
Orchestra BioMed Holdings reports return on equity of -98.4%, an operating margin of -195.4% and revenue down 89.4% year over year.
It holds more cash than debt, a net cash position of 28.36M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 13.29 USD is 101.9% above the current price. The next earnings report is expected on 11 March 2027.